drugset / Trial / NCT06984159

The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

NCT06984159

Phase 3 Completed 137 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer

Timeline

Start
2022-07-12
Primary completion
2023-11-30
Completion
2024-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified Subcutaneous

Indications